Clin2
NCT07216859Likely a fitNot yet recruiting

AI heart test to check for liver disease risk

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseCirrhosis

Part of Digestive system, Heart & circulation, Hormones & metabolism clinical trials.

This trial uses an AI tool to review routine heart ultrasound images and find people who may be at high risk for fatty liver disease or cirrhosis. It aims to connect participants with further testing and care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
2,000 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You had a routine heart ultrasound (echocardiogram) recently.
  • The AI tool found your ultrasound suggests a high chance of fatty liver disease or cirrhosis.
  • You can give consent and be reached for follow-up.
  • You are willing to have additional testing for liver disease.
  • You have not had a liver or kidney transplant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease

This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.

London, London
NCT06986447Enrolling by invitation
Non-invasive tests for serious liver disease

This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.

Chandler, Arizona
NCT07270601Recruiting
Ultrasound test for liver fat

This study is testing a new ultrasound method to measure fat in the liver. It is for people who may have a liver condition or have risk factors like diabetes or obesity, as well as healthy volunteers.

Seattle, Washington
NCT06664866Enrolling by invitation
AI Screening for Heart Amyloidosis

This trial tests an AI program that looks at your heart ultrasound (echocardiogram) to find possible signs of cardiac amyloidosis early. It helps doctors decide if more testing is needed.

Los Angeles, California
NCT05139797Recruiting
AI-guided heart ultrasound screening for suspected amyloidosis

This study tests whether an artificial-intelligence system can help decide who should get a special heart workup for a rare disease called cardiac amyloidosis. If you have signs that make doctors suspect this, the AI-guided ultrasound screening may help find it sooner.

Los Angeles, California
NCT07613827Enrolling by invitation
AI screening for fatty liver disease using CT scans

This study uses artificial intelligence to help doctors identify fatty liver disease from CT scans you may already be having. If eligible, you'll have some blood tests and possibly an ultrasound or MRI to confirm liver health, helping catch liver disease early.

Shenyang, Liaoning

Hear when a new Cirrhosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.